Previous close | 7.9000 |
Open | 0.6400 |
Bid | 0.1800 |
Ask | 0.2200 |
Strike | 275.00 |
Expiry date | 2024-05-17 |
Day's range | 0.1400 - 2.6500 |
Contract range | N/A |
Volume | |
Open interest | 346 |
Shares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development to treat obesity. The pharmaceutical giant beat first-quarter revenue estimates while reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins The Morning Brief to break down the latest developments from Amgen and its outlook on use cases for the drug in question, MariTide. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino
Buyers dictated the action in the stock market today. The Nasdaq gapped powerfully above a key level on news of soft job growth in April.
Wall Street's main indexes advanced on Friday after a softer-than-expected jobs report revived hopes of the Federal Reserve cutting interest rates this year, while gains in Apple and Amgen on upbeat corporate updates added support. U.S. job growth slowed more than expected in April and the increase in annual wages fell below 4% for the first time in nearly three years, while the unemployment rate stood at 3.9% compared with expectations that it would remain steady at 3.8%.